Somatostatin Receptor Positive Clinical Trials in Barcelona
2 recruitingBarcelona, Spain
Showing 1–2 of 2 trials
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals240 enrolled65 locationsNCT06784752
Recruiting
Phase 1
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Solid TumorLymphomaGIST+5 more
ITM Solucin GmbH20 enrolled5 locationsNCT06441331